"“DNA or RNA-based tests have repeatedly shown greater sensitivity and specificity over commonly used rapid immunochemistry-based testing methods, but have not been simplified to the extent that they can be moved to a POC setting,” explains David Mead, Ph.D., Lucigen founder and CEO. “We're developing the world’s first nucleic acid-based test for viral infections that is cost effective and can be safely and easily used directly at the physician’s office.” Lucigen believes the platform could form the basis of a multiplex system for testing a range of serious infectious agents at low resource and battlefield settings, and potentially in the future be developed as an OTC device."
Source:
